Patent ID: 8206706

Claim:
A method of inhibiting IGF-1 actions in a subject in need thereof, comprising administering to said subject an α V β 3 integrin cysteine loop domain antagonist in an amount effective to inhibit IGF-1 actions in said subject, wherein said antagonist is an antibody that: (a) specifically binds to the cysteine loop domain at amino acids 177 to 184 of a human β 3 integrin, wherein said amino acids consist of SEQ ID NO:82; (b) does not specifically bind to the RGD binding site of a human β 3 integrin; and (c) specifically binds to the cysteine loop domain at amino acids 177 to 184 of a pig β 3 integrin, wherein said amino acids consist of SEQ ID NO: 82 and wherein said subject has atherosclerosis, and said antagonist is administered in an amount effective to treat said atherosclerosis.